ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Research Report 2024
Published Date: April 2024
|
Report Code: QYRE-Auto-22B12205
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Carcinoembryonic Antigen related Cell Adhesion Molecule 5 CEACAM5 Antibody Market Research Report 2022
BUY CHAPTERS

Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Research Report 2024

Code: QYRE-Auto-22B12205
Report
April 2024
Pages:100
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sino Biological Inc
Lifespan Biosciences Inc.
Abcam
Thermo Fisher Scientific (China) Co., Ltd.
Bio-Techne
Boster Biological Technology
Merck
RayBiotech
Assay Genie
Creative-Biolabs
MyBioSource
OriGene Technologies, Inc.
Creative Diagnostics
Abbexa
Biorbyt
Abeomics
Cusabio
Enzo Life sciences Inc

Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size

The global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market was valued at US$ 394.6 million in 2023 and is anticipated to reach US$ 894.4 million by 2030, witnessing a CAGR of 12.4% during the forecast period 2024-2030.

Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market

Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market

Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody is an antibody specific for CEACAM5 protein. CEACAM5, also known as fetal antigen 5 (CEA), is a membranous cell adhesion molecule that is often expressed on the surface of a variety of cancer cells, especially in cancers of the digestive tract, pancreas, and breast.
This antibody can bind to CEACAM5 protein to help detect and localize cancer cells, and can also be used in immunohistochemistry and cancer diagnosis. Due to the high expression of CEACAM5 in cancer, CEACAM5 antibodies have potential applications in tumor marker research and clinical diagnosis, helping to detect and monitor early cancer.
This report aims to provide a comprehensive presentation of the global market for Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody.

Report Scope

The Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Report

Report Metric Details
Report Name Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market
Accounted market size in 2023 US$ 394.6 million
Forecasted market size in 2030 US$ 894.4 million
CAGR 12.4%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • Monoclonal Antibody
  • Polyclonal Antibody
Segment by Application
  • Flow Cytometry
  • ELISA
  • Western Blot
  • Immunoprecipitation
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Sino Biological, Inc., LifeSpan BioSciences, Inc, Abcam, Thermo Fisher Scientific (China) Co., Ltd., Bio-Techne, Boster Biological Technology, Merck, RayBiotech, Inc., Assay Genie, Creative Biolabs, MyBiosource, Inc., OriGene Technologies, Inc., Creative Diagnostics, Abbexa, Biorbyt, Abeomics Inc., CUSABIO, Enzo Life Sciences, Inc.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market growing?

Ans: The Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market witnessing a CAGR of 12.4% during the forecast period 2024-2030.

What is the Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market size in 2030?

Ans: The Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market size in 2030 will be US$ 894.4 million.

Who are the main players in the Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market report?

Ans: The main players in the Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market are Sino Biological, Inc., LifeSpan BioSciences, Inc, Abcam, Thermo Fisher Scientific (China) Co., Ltd., Bio-Techne, Boster Biological Technology, Merck, RayBiotech, Inc., Assay Genie, Creative Biolabs, MyBiosource, Inc., OriGene Technologies, Inc., Creative Diagnostics, Abbexa, Biorbyt, Abeomics Inc., CUSABIO, Enzo Life Sciences, Inc.

What are the Application segmentation covered in the Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market report?

Ans: The Applications covered in the Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market report are Flow Cytometry, ELISA, Western Blot, Immunoprecipitation, Others

What are the Type segmentation covered in the Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market report?

Ans: The Types covered in the Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market report are Monoclonal Antibody, Polyclonal Antibody

1 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Overview
1.1 Product Overview and Scope of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody
1.2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Segment by Type
1.2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Value Comparison by Type (2024-2030)
1.2.2 Monoclonal Antibody
1.2.3 Polyclonal Antibody
1.3 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Segment by Application
1.3.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Value by Application: (2024-2030)
1.3.2 Flow Cytometry
1.3.3 ELISA
1.3.4 Western Blot
1.3.5 Immunoprecipitation
1.3.6 Others
1.4 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size Estimates and Forecasts
1.4.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue 2019-2030
1.4.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales 2019-2030
1.4.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Competition by Manufacturers
2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Manufacturers (2019-2024)
2.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Average Price by Manufacturers (2019-2024)
2.4 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Product Type & Application
2.7 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Competitive Situation and Trends
2.7.1 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Players Market Share by Revenue
2.7.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Retrospective Market Scenario by Region
3.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region: 2019-2030
3.2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region: 2019-2024
3.2.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region: 2025-2030
3.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region: 2019-2030
3.3.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region: 2019-2024
3.3.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region: 2025-2030
3.4 North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Facts & Figures by Country
3.4.1 North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2019-2030)
3.4.3 North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Facts & Figures by Country
3.5.1 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2019-2030)
3.5.3 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Facts & Figures by Country
3.6.1 Asia Pacific Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2019-2030)
3.6.3 Asia Pacific Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Facts & Figures by Country
3.7.1 Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2019-2030)
3.7.3 Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Facts & Figures by Country
3.8.1 Middle East and Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2019-2030)
3.8.3 Middle East and Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2019-2030)
4.1.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2019-2024)
4.1.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2025-2030)
4.1.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Type (2019-2030)
4.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2019-2030)
4.2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2019-2024)
4.2.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2025-2030)
4.2.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Type (2019-2030)
4.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price by Type (2019-2030)
5 Segment by Application
5.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2019-2030)
5.1.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2019-2024)
5.1.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2025-2030)
5.1.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Application (2019-2030)
5.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2019-2030)
5.2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2019-2024)
5.2.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2025-2030)
5.2.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Application (2019-2030)
5.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Sino Biological, Inc.
6.1.1 Sino Biological, Inc. Corporation Information
6.1.2 Sino Biological, Inc. Description and Business Overview
6.1.3 Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.1.5 Sino Biological, Inc. Recent Developments/Updates
6.2 LifeSpan BioSciences, Inc
6.2.1 LifeSpan BioSciences, Inc Corporation Information
6.2.2 LifeSpan BioSciences, Inc Description and Business Overview
6.2.3 LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.2.4 LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.2.5 LifeSpan BioSciences, Inc Recent Developments/Updates
6.3 Abcam
6.3.1 Abcam Corporation Information
6.3.2 Abcam Description and Business Overview
6.3.3 Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.3.5 Abcam Recent Developments/Updates
6.4 Thermo Fisher Scientific (China) Co., Ltd.
6.4.1 Thermo Fisher Scientific (China) Co., Ltd. Corporation Information
6.4.2 Thermo Fisher Scientific (China) Co., Ltd. Description and Business Overview
6.4.3 Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.4.5 Thermo Fisher Scientific (China) Co., Ltd. Recent Developments/Updates
6.5 Bio-Techne
6.5.1 Bio-Techne Corporation Information
6.5.2 Bio-Techne Description and Business Overview
6.5.3 Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.5.5 Bio-Techne Recent Developments/Updates
6.6 Boster Biological Technology
6.6.1 Boster Biological Technology Corporation Information
6.6.2 Boster Biological Technology Description and Business Overview
6.6.3 Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.6.5 Boster Biological Technology Recent Developments/Updates
6.7 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 RayBiotech, Inc.
6.8.1 RayBiotech, Inc. Corporation Information
6.8.2 RayBiotech, Inc. Description and Business Overview
6.8.3 RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.8.4 RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.8.5 RayBiotech, Inc. Recent Developments/Updates
6.9 Assay Genie
6.9.1 Assay Genie Corporation Information
6.9.2 Assay Genie Description and Business Overview
6.9.3 Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.9.5 Assay Genie Recent Developments/Updates
6.10 Creative Biolabs
6.10.1 Creative Biolabs Corporation Information
6.10.2 Creative Biolabs Description and Business Overview
6.10.3 Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.10.5 Creative Biolabs Recent Developments/Updates
6.11 MyBiosource, Inc.
6.11.1 MyBiosource, Inc. Corporation Information
6.11.2 MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Description and Business Overview
6.11.3 MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.11.4 MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.11.5 MyBiosource, Inc. Recent Developments/Updates
6.12 OriGene Technologies, Inc.
6.12.1 OriGene Technologies, Inc. Corporation Information
6.12.2 OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Description and Business Overview
6.12.3 OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.12.4 OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.12.5 OriGene Technologies, Inc. Recent Developments/Updates
6.13 Creative Diagnostics
6.13.1 Creative Diagnostics Corporation Information
6.13.2 Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Description and Business Overview
6.13.3 Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.13.5 Creative Diagnostics Recent Developments/Updates
6.14 Abbexa
6.14.1 Abbexa Corporation Information
6.14.2 Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Description and Business Overview
6.14.3 Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.14.5 Abbexa Recent Developments/Updates
6.15 Biorbyt
6.15.1 Biorbyt Corporation Information
6.15.2 Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Description and Business Overview
6.15.3 Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.15.5 Biorbyt Recent Developments/Updates
6.16 Abeomics Inc.
6.16.1 Abeomics Inc. Corporation Information
6.16.2 Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Description and Business Overview
6.16.3 Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.16.5 Abeomics Inc. Recent Developments/Updates
6.17 CUSABIO
6.17.1 CUSABIO Corporation Information
6.17.2 CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Description and Business Overview
6.17.3 CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.17.4 CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.17.5 CUSABIO Recent Developments/Updates
6.18 Enzo Life Sciences, Inc.
6.18.1 Enzo Life Sciences, Inc. Corporation Information
6.18.2 Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Description and Business Overview
6.18.3 Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolio
6.18.5 Enzo Life Sciences, Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Industry Chain Analysis
7.2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Production Mode & Process
7.4 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Marketing
7.4.1 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Channels
7.4.2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Distributors
7.5 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Customers
8 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Dynamics
8.1 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Industry Trends
8.2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Drivers
8.3 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Challenges
8.4 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Sino Biological Inc
Lifespan Biosciences Inc.
Abcam
Thermo Fisher Scientific (China) Co., Ltd.
Bio-Techne
Boster Biological Technology
Merck
RayBiotech
Assay Genie
Creative-Biolabs
MyBioSource
OriGene Technologies, Inc.
Creative Diagnostics
Abbexa
Biorbyt
Abeomics
Cusabio
Enzo Life sciences Inc
List of Tables
    Table 1. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units) of Key Manufacturers (2019-2024)
    Table 5. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Average Price (US$/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Product Type & Application
    Table 12. Global Key Manufacturers of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2019-2024) & (K Units)
    Table 18. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Region (2019-2024)
    Table 19. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2025-2030) & (K Units)
    Table 20. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Region (2025-2030)
    Table 21. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Region (2019-2024)
    Table 23. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Region (2025-2030)
    Table 25. North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2019-2024) & (K Units)
    Table 27. North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2025-2030) & (K Units)
    Table 28. North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2019-2024) & (K Units)
    Table 32. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2025-2030) & (K Units)
    Table 33. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2019-2024) & (K Units)
    Table 37. Asia Pacific Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2025-2030) & (K Units)
    Table 38. Asia Pacific Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2019-2024) & (K Units)
    Table 42. Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2025-2030) & (K Units)
    Table 43. Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2019-2024) & (K Units)
    Table 47. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2025-2030) & (K Units)
    Table 48. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units) by Type (2019-2024)
    Table 51. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units) by Type (2025-2030)
    Table 52. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Type (2019-2024)
    Table 53. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Type (2025-2030)
    Table 54. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Type (2019-2024)
    Table 57. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Type (2025-2030)
    Table 58. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price (US$/Unit) by Type (2019-2024)
    Table 59. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price (US$/Unit) by Type (2025-2030)
    Table 60. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units) by Application (2019-2024)
    Table 61. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units) by Application (2025-2030)
    Table 62. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Application (2019-2024)
    Table 63. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Application (2025-2030)
    Table 64. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Application (2019-2024)
    Table 67. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Application (2025-2030)
    Table 68. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price (US$/Unit) by Application (2019-2024)
    Table 69. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price (US$/Unit) by Application (2025-2030)
    Table 70. Sino Biological, Inc. Corporation Information
    Table 71. Sino Biological, Inc. Description and Business Overview
    Table 72. Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 73. Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 74. Sino Biological, Inc. Recent Developments/Updates
    Table 75. LifeSpan BioSciences, Inc Corporation Information
    Table 76. LifeSpan BioSciences, Inc Description and Business Overview
    Table 77. LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 78. LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 79. LifeSpan BioSciences, Inc Recent Developments/Updates
    Table 80. Abcam Corporation Information
    Table 81. Abcam Description and Business Overview
    Table 82. Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 83. Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 84. Abcam Recent Developments/Updates
    Table 85. Thermo Fisher Scientific (China) Co., Ltd. Corporation Information
    Table 86. Thermo Fisher Scientific (China) Co., Ltd. Description and Business Overview
    Table 87. Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 88. Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 89. Thermo Fisher Scientific (China) Co., Ltd. Recent Developments/Updates
    Table 90. Bio-Techne Corporation Information
    Table 91. Bio-Techne Description and Business Overview
    Table 92. Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 93. Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 94. Bio-Techne Recent Developments/Updates
    Table 95. Boster Biological Technology Corporation Information
    Table 96. Boster Biological Technology Description and Business Overview
    Table 97. Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 98. Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 99. Boster Biological Technology Recent Developments/Updates
    Table 100. Merck Corporation Information
    Table 101. Merck Description and Business Overview
    Table 102. Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 103. Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 104. Merck Recent Developments/Updates
    Table 105. RayBiotech, Inc. Corporation Information
    Table 106. RayBiotech, Inc. Description and Business Overview
    Table 107. RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 108. RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 109. RayBiotech, Inc. Recent Developments/Updates
    Table 110. Assay Genie Corporation Information
    Table 111. Assay Genie Description and Business Overview
    Table 112. Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 113. Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 114. Assay Genie Recent Developments/Updates
    Table 115. Creative Biolabs Corporation Information
    Table 116. Creative Biolabs Description and Business Overview
    Table 117. Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 118. Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 119. Creative Biolabs Recent Developments/Updates
    Table 120. MyBiosource, Inc. Corporation Information
    Table 121. MyBiosource, Inc. Description and Business Overview
    Table 122. MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 123. MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 124. MyBiosource, Inc. Recent Developments/Updates
    Table 125. OriGene Technologies, Inc. Corporation Information
    Table 126. OriGene Technologies, Inc. Description and Business Overview
    Table 127. OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 128. OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 129. OriGene Technologies, Inc. Recent Developments/Updates
    Table 130. Creative Diagnostics Corporation Information
    Table 131. Creative Diagnostics Description and Business Overview
    Table 132. Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 133. Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 134. Creative Diagnostics Recent Developments/Updates
    Table 135. Abbexa Corporation Information
    Table 136. Abbexa Description and Business Overview
    Table 137. Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 138. Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 139. Abbexa Recent Developments/Updates
    Table 140. Biorbyt Corporation Information
    Table 141. Biorbyt Description and Business Overview
    Table 142. Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 143. Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 144. Biorbyt Recent Developments/Updates
    Table 145. Abeomics Inc. Corporation Information
    Table 146. Abeomics Inc. Description and Business Overview
    Table 147. Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 148. Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 149. Abeomics Inc. Recent Developments/Updates
    Table 150. CUSABIO Corporation Information
    Table 151. CUSABIO Description and Business Overview
    Table 152. CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 153. CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 154. CUSABIO Recent Developments/Updates
    Table 155. Enzo Life Sciences, Inc. Corporation Information
    Table 156. Enzo Life Sciences, Inc. Description and Business Overview
    Table 157. Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 158. Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product
    Table 159. Enzo Life Sciences, Inc. Recent Developments/Updates
    Table 160. Key Raw Materials Lists
    Table 161. Raw Materials Key Suppliers Lists
    Table 162. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Distributors List
    Table 163. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Customers List
    Table 164. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Trends
    Table 165. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Drivers
    Table 166. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Challenges
    Table 167. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Restraints
    Table 168. Research Programs/Design for This Report
    Table 169. Key Data Information from Secondary Sources
    Table 170. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody
    Figure 2. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Share by Type in 2023 & 2030
    Figure 4. Monoclonal Antibody Product Picture
    Figure 5. Polyclonal Antibody Product Picture
    Figure 6. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 7. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Share by Application in 2023 & 2030
    Figure 8. Flow Cytometry
    Figure 9. ELISA
    Figure 10. Western Blot
    Figure 11. Immunoprecipitation
    Figure 12. Others
    Figure 13. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size (2019-2030) & (US$ Million)
    Figure 15. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (2019-2030) & (K Units)
    Figure 16. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Average Price (US$/Unit) & (2019-2030)
    Figure 17. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Report Years Considered
    Figure 18. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Share by Manufacturers in 2023
    Figure 19. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Share by Manufacturers in 2023
    Figure 20. The Global 5 and 10 Largest Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Players: Market Share by Revenue in 2023
    Figure 21. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 22. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 23. North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Country (2019-2030)
    Figure 24. North America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Country (2019-2030)
    Figure 25. United States Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 26. Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 27. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Country (2019-2030)
    Figure 28. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Country (2019-2030)
    Figure 29. Germany Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. France Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. U.K. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. Italy Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 33. Russia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 34. Asia Pacific Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Region (2019-2030)
    Figure 35. Asia Pacific Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Region (2019-2030)
    Figure 36. China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. Japan Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. South Korea Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. India Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. Australia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. China Taiwan Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. Southeast Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 43. Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Country (2019-2030)
    Figure 44. Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Country (2019-2030)
    Figure 45. Mexico Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 46. Brazil Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 47. Argentina Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 48. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Country (2019-2030)
    Figure 49. Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Country (2019-2030)
    Figure 50. Turkey Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 51. Saudi Arabia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 52. UAE Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 53. Global Sales Market Share of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Type (2019-2030)
    Figure 54. Global Revenue Market Share of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Type (2019-2030)
    Figure 55. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price (US$/Unit) by Type (2019-2030)
    Figure 56. Global Sales Market Share of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Application (2019-2030)
    Figure 57. Global Revenue Market Share of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Application (2019-2030)
    Figure 58. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price (US$/Unit) by Application (2019-2030)
    Figure 59. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Value Chain
    Figure 60. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Production Process
    Figure 61. Channels of Distribution (Direct Vs Distribution)
    Figure 62. Distributors Profiles
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Carcinoembryonic Antigen related Cell Adhesion Molecule 5 CEACAM5 ELISA Kit Market Research Report 2024
Global CEACAM1Antibody Market Research Report 2024
Global CEA ELISA Kits Market Research Report 2024
Global CEA Test Kits Market Research Report 2024
Global Carbohydrate Antigen 19 9 Market Insights Forecast to 2030
Global Tumor Specific Antigen Market Size Status and Forecast 2019 2025
Global CD Antigen Cancer Therapy Market Research Report 2025
Global Carbohydrate Antigen 19 9 Quantitative Determination Kit Market Research Report 2024
Global Carcinoembryonic Antigen Quantitative Determination Kit Market Research Report 2024
Global Carcinoembryonic Antigen Quantitative Assay Kit Market Research Report 2024
Global Carcinoembryonic Antigen Assay Kit Market Research Report 2024
Global Cancer Rapid Diagnostic Test Box Market Research Report 2025
Global Cancer Rapid Diagnostic Kit Market Research Report 2025
Global CTLA 4 Antibody Market Research Report 2024
Global Cancer Antigen Market Research Report 2024
Global Beta Catenin Antibody Market Research Report 2024
Global Death Receptor 5 DR5 Antibody Market Research Report 2024
Global Nuclear Antigen Antibody Market Research Report 2024
Global DNAM 1 Antibody Market Research Report 2024
Global Monoclonal Antibodies for Non small Cell Lung Cancer Market Research Report 2025

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions